Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | D3S-002 |
Synonyms | |
Therapy Description |
D3S-002 selectively inhibits Erk1 and Erk2, potentially leading to decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 5501). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
D3S-002 | D3S 002|D3S002 | ERK Inhibitor (pan) 21 | D3S-002 selectively inhibits Erk1 and Erk2, potentially leading to decreased tumor growth (Cancer Res (2023) 83 (7_Supplement): 5501). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05886920 | Phase I | D3S-002 | Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations | Recruiting | USA | AUS | 1 |